IL10 and neoplasm: Pegylated IL-10 (PEG-IL-10), which in pre-clinical tumor models was shown to expand tumor-resident CD8+ T cells and mediate tumor rejection (217), has entered human trials as monotherapy or in combination with chemotherapy for patients with advanced solid tumors, which include melanoma, NSCLC, renal cell, colorectal, ovarian, prostate, and pancreatic cancers (Clinical Trial NCT02009449) (Bauer 2014 ASCO).